Anticancer activity of a peptide combination in gastrointestinal cancers targeting multiple neuropeptide receptors

Investigational New Drugs

Volumn 26, Issue 6, 2008, Pages 489-504

  Jaggi, Manu ^a   Prasad, Sudhanand ^a   Singh, Anu T ^a   Praveen, R ^a   Dutt, Sarjana ^a   Mathur, Archana ^a   Sharma, Rajan ^a   Gupta, Neena ^a   Ahuja, Rinku ^a   Mukherjee, Rama ^a   Burman, Anand C ^a  

^a DABUR RESEARCH FOUNDATION   (India)

Author keywords

Cytotoxicity; Gastrointestinal cancer; Long term safety; Neuropeptides; Peptide design; Xenograft

Indexed keywords

BOMBESIN; DEXTRO ARGINYLPROLYLLYSYLPROLYL DEXTRO PHENYLALANYLGLUTAMINYL DEXTRO TRYPTOPHYLPHENYLALANYL DEXTRO TRYPTOPHYLLEUCYL 1 AMINOCYCLOPENTANE CARBOXYLIC ACID AMIDE; DEXTRO PHENYLALANYLCYSTEINYLTYROSYL DEXTRO TRYPTOPHYLORNITHYLTHREONYLPENICILLAMINYLTHREONINAMIDE; DEXTRO PHENYLALANYLGLUTAMINYLTRYPTOPHYLALANYLVALYL ALPHA,ALPHA AMINOISOBUTYRIC ACID HISTIDYLLEUCINAMIDE; DRF 7295; LEUCYLMETHIONYLTYROSYLPROLYLTHREONYLLEUCYLLYSINE; NEUROPEPTIDE; NEUROPEPTIDE RECEPTOR; PEPTIDE DERIVATIVE; SOMATOSTATIN; SUBSTANCE P; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; COLON ADENOCARCINOMA; CONTROLLED STUDY; DIGESTIVE SYSTEM CANCER; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG SYNTHESIS; FEMALE; GLIOBLASTOMA; HUMAN; LEUKEMIA; MALE; MOUSE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SINGLE DRUG DOSE; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BOMBESIN; CELL LINE, TUMOR; DRUG COMBINATIONS; DRUG DELIVERY SYSTEMS; FEMALE; GASTROINTESTINAL NEOPLASMS; HUMANS; MALE; MICE; MICE, NUDE; PEPTIDES; RATS; RATS, WISTAR; RECEPTORS, BOMBESIN; RECEPTORS, NEUROKININ-1; RECEPTORS, SOMATOSTATIN; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; SOMATOSTATIN; SUBSTANCE P; TOXICITY TESTS; VASOACTIVE INTESTINAL PEPTIDE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 53749100876     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-008-9117-4     Document Type: Article

References (44)

1. JP Burbach OC Meijer 1992 The structure of neuropeptide receptors Eur J Pharmacol 227 1 18
2. Rozengurt E (1996) Neuropeptides growth factors: signaling pathways and role in cancer. In: Pusztai LL, Lewis CE, Yap E (eds) Cell proliferation in cancer: regulatory mechanisms of neoplastic cell growth. Oxford University press, New York, pp 247-259
3. RE Favoni A De Cupis 2000 The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach Pharmacol Rev 52 179 206
4. Pimentel (1994) Growth factors and neoplasia. In: Handbook of Growth factors, vol. 1. CRC, USA, pp 329-337
5. Y Matsumoto M Kawatani S Simizu T Tanaka M Takada M Imoto 2000 Bcl-2-independent induction of apoptosis by neuropeptide receptor antagonist in human small cell lung carcinoma cells Anticancer Res 20 3123 3129
6. R Danesi M Del Tacca 1996 The effects of the somatostatin analog octreotide on angiogenesis in vitro Metabolism 45 49 50
7. EA Woltering R Barrie TM O'Dorisio D Arce T Ure A Cramer D Holmes J Robertson J Fassler 1991 Somatostatin analogues inhibit angiogenesis in the chick chorioallantoic membrane J Surg Res 50 245 251
8. JC Reubi 2003 Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr Rev 24 389 427
9. YL Janin 2003 Peptides with anticancer use or potential Amino Acids 25 1 40
10. AV Schally K Szepeshazi A Nagy AM Comaru-Schally G Halmos 2004 New approaches to therapy of cancers of the stomach, colon and pancreas based on peptide analogs Cell Mol Life Sci 61 1042 1068
11. H Frucht AF Gazdar JA Park H Oie RT Jensen 1992 Characterization of functional receptors for gastrointestinal hormones on human colon cancer cells Cancer Res 52 1114 1122
12. Cancer Facts and Figures 2004, American Cancer Society, Inc, ©2004
13. BJ Kennedy 1964 Chemotherapy of colon cancer J Lancet 84 131 133
14. T Andre C Louvet A De Gramont 2004 Colon cancer: what is new in 2004? Bull Cancer 91 75 80
15. AH Braun W Achterrath H Wilke U Vanhoefer A Harstrick P Preusser 2004 New systemic frontline treatment for metastatic colorectal carcinoma Cancer 100 1558 1577
16. Mukherjee R, Jaggi M (2000). Drug for treatment of cancer. US Patent 6,156,725
17. H Singh A Kumar M Courtney JR Townshed Z Samad PA Singh 1988 A Synthetic peptide, L-8-K, and its antibody both inhibit the specific binding of vasoactive intestinal peptide to hamster pancreatic cancer cells Ann NY Acad Sci 527 679 681
18. Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT (2003). Substance P analogs for the treatment of cancer. US Patent 6,596,692
19. Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT, Mathur A (2001) Somatostatin analogs for the treatment of cancer. US Patent 6,316,414
20. Burman AC, Prasad S, Mukherjee R, Jaggi M, Singh AT, Mathur A. Bombesin analogs for the treatment of cancer. US Patent appl. 09/630,999
21. F Cuttitta DN Carney J Mulshine TW Moody J Fedorko A Fischler JD Minna 1985 Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer Nature 316 823 826
22. E Rozengurt 1990 Bombesin stimulation of mitogenesis. Specific receptors, signal transduction, and early events Am Rev Respir Dis 142 S11 S15
23. AG Aprikian L Tremblay K Han S Chevalier 1997 Bombesin stimulates the motility of human prostate-cancer cells via the tyrosine phosphorylation of focal adhesion kinase and integrin-associated proteins Int J Cancer 72 498 504
24. M Gugger JC Reubi 1999 Gastrin-releasing peptide receptors in non-neoplastic and neoplastic human breast Am J Pathol 155 2067 2076
25. R Markwalder JC Reubi 1999 Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation Cancer Res 59 1152 1159
26. RZ Cai H Reile P Armatis AV Schally 1994 Potent bombesin antagonists with C-Terminal Leu-(CH2-N)-Tac-NH2 or its derivatives Proc Natl Acad Sci U S A 91 12664 12668
27. DH Coy JE Taylor NY Jiang SH Kim LH Wang SC Huang JP Moreau JD Gardner RT Jensen 1989 Short-chain pseudopeptide bombesin receptor antagonists with enhanced binding affinities for pancreatic acinar and Swiss 3T3 cells display strong antimitotic activity J Biol Chem 264 14691 14697
28. SA Mantey DH Coy LK Entsuah RT Jensen 2004 Development of bombesin analogs with conformationally restricted amino acid substitutions with enhanced selectivity for the orphan receptor human bombesin receptor subtype 3 J Pharmacol Exp Ther 310 1161 1170
29. I Zachary E Rozengurt 1986 A substance P antagonist also inhibits specific binding and mitogenic effects of vasopressin and bombesin-related peptides in Swiss 3T3 cells Biochem Biophys Res Commun 137 135 141
30. 11] substance P, a potent bombesin antagonist in murine Swiss 3T3 cells, inhibits the growth of human small cell lung cancer cells in vitro Proc Natl Acad Sci U S A 85 1859 1863
31. G Weckbecker I Lewis R Albert HA Schmid D Hoyer C Bruns 2003 Opportunities in somatostatin research: biological, chemical and therapeutic aspects Nat Rev Drug Discov 2 999 1017
32. C Scarpignato I Pelosini 2001 Somatostatin analogs for cancer treatment and diagnosis: an overview Chemotherapy 47 1 29
33. A Janecka M Zubrzycka T Janecki 2001 Somatostatin analogs J Pept Res 58 91 107
34. IL Karle P Balaram 1990 Structural characteristics of alpha-helical peptide molecules containing Aib residues Biochemistry 29 6747 6756
35. IL Karle R Gurunath S Prasad R Kaul BR Rao P Balaram 1995 Peptide design. Structural evaluation of potential nonhelical segments attached to helical modules J Am Chem Soc 117 9632 9637
36. S Prasad BR Rao P Balaram 1995 Contrasting solution conformations of peptides containing a, a-dialkylated residues with linear and cyclic side chains Biopolymers 35 11 20
37. S Prasad RB Rao H Bergstrand B Lundquist EL Becker P Balaram 1996 Conformation-activity correlations for chemotactic tripeptide analogs incorporating dialkyl residues with linear and cyclic sidechains at position 2 Int J Pept Protein Res 48 312 318
38. W Kazmierski WS Wire GK Lui RJ Knapp JE Shook TF Burks HI Yamamura VJ Hruby 1988 Design and synthesis of somatostatin analogues with topographical properties that lead to highly potent and specific mu opioid receptor antagonists with greatly reduced binding at somatostatin receptors J Med Chem 31 2170 2177
39. M Jaggi R Mukherjee 1992 A modified colorimetric assay (MTT) for testing cytotoxicity of anti cancer drugs on primary tumor cells Anticancer Res 12 6B 2340
40. Mukherjee R, Jaggi M. Method for establishing a tumor-cell line by preparing single-cell suspension of tumor cells from tumor biopsies. US Patent 5744363
41. Jaggi M, Mukherjee R (1992) Experimental approaches to establishment of primary cultures of adenocarcinoma cells and their in vivo transfer for tumor formation to test anticancer drugs. Anticancer Res 12(6A)
42. M Jaggi R Mukherjee 1994 New, sensitive and specific ELISA for the detection of neuropeptides in culture supernatants J Immunoass 15 129 146
43. JA Quin SA Sgambati JR Goldenring MD Basson LP Fielding IM Modlin GH Ballantyne 1995 PYY inhibition of VIP-stimulated ion transport in the rabbit distal ileum J Surg Res 58 111 115
44. Mukherjee R, Doval DC, Raghunadharao D, Majumdar A, Ganguly S, Jaggi M, Prasad S, Singh AT Burman AC (2003) Phase I dose escalating study of DRF7295: a new class of peptide based drugs. ASCO, Abstract ID: 948